Target-04

Target-04 is an early-stage therapeutic program currently in the discovery phase at Verge Genomics, specifically targeting Amyotrophic Lateral Sclerosis (ALS). The program was identified through the company's proprietary "all-in-human" AI-driven platform, which integrates human genomic data with advanced computational modeling to discover novel disease-relevant targets. While the specific biological target and therapeutic modality for Target-04 have not been publicly disclosed, the program represents Verge's strategy of moving beyond traditional animal models to identify targets with higher clinical translation potential.